Scancell Holdings (LSE:SCLP) EBIT per Share : £-0.01 (TTM As of Oct. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Scancell Holdings EBIT per Share?

Scancell Holdings's EBIT per Share for the six months ended in Oct. 2023 was £-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2023 was £-0.01.

During the past 5 years, the average EBIT per Share Growth Rate was 0.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was -3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Scancell Holdings's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Scancell Holdings was 51.30% per year. The lowest was -21.60% per year. And the median was -4.90% per year.

LSE:SCLP's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.45
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Scancell Holdings's EBIT for the six months ended in Oct. 2023 was £-3.10 Mil.

Scancell Holdings EBIT per Share Historical Data

The historical data trend for Scancell Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings EBIT per Share Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

EBIT per Share

Get a 7-Day Free Trial

-0.02

-0.01

-0.02

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
EBIT per Share	Get a 7-Day Free Trial															0.01	-0.01	-0.01	-0.01	-

Scancell Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Scancell Holdings's EBIT per Share for the fiscal year that ended in Apr. 2023 is calculated as

	EBIT per Share		(A: Apr. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-13.089	/	816.368
=	-0.02

Scancell Holdings's EBIT per Share for the quarter that ended in Oct. 2023 is calculated as

	EBIT per Share		(Q: Oct. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.095	/	819.342
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01

Scancell Holdings (LSE:SCLP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Scancell Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (LSE:SCLP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCP:Germany

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines